$3.00
+1.0%Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
GNLX • NASDAQ
| Genelux Corporation Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||
-32.1M | -29.9M | -28.3M | -5.2M | -16.4M | -13.6M | -11.6M | |
244K | 903K | 1M | 968K | 895K | 658K | 477K | |
0.0 | 0.0 | 0.0 | 0.0 | 348K | 0.0 | 0.0 | |
5.9M | 6.1M | 5.2M | 2.4M | 4.3M | 5.3M | 0.0 | |
1.8M | 917K | 5.1M | -56K | 196K | 74K | 3.8M | |
-1M | 751K | -3.3M | -1.7M | 4.1M | 381K | 84K | |
-25.3M | -21.2M | -20.3M | -3.6M | -6.6M | -7.2M | -7.2M | |
INVESTING ACTIVITIES | |||||||
-1.1M | -381K | -1M | -49K | (0.0) | -20K | -1.8M | |
-18.3M | -29M | -13.7M | (0.0) | (0.0) | (0.0) | (0.0) | |
31.5M | 21.3M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
(12.1M) | -8.1M | -14.7M | -49K | (0.0) | -20K | -1.8M | |
FINANCING ACTIVITIES | |||||||
9.9M | 27.8M | 39.6M | 0.0 | 143K | 9M | 6.4M | |
0.0 | 0.0 | 215K | 970K | -558K | 9.2M | 1.5M | |
0.0 | 688K | 4.2M | -1.4M | 145K | 0.0 | 0.0 | |
9.9M | 28.5M | 44M | -478K | -270K | 18.2M | 7.9M | |
CASH FLOW SUMMARY | |||||||
-3.2M | -853K | 9M | -4.1M | -6.9M | 10.9M | -1.1M | |
8.6M | 9.4M | 397K | 4.5M | 11.4M | 425K | 1.5M | |
5.3M | 8.6M | 9.4M | 397K | 4.5M | 11.4M | 425K | |
-26.4M | -21.6M | -21.3M | -3.6M | -6.6M | -7.2M | -9M |
GNLX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 29, 2026 | April 29, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 19, 2026 | March 19, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 19, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 02, 2026 | February 02, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 08, 2026 | January 08, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 05, 2026 | January 05, 2026 | 2026 | |
8-K 8-K 2025 N/A | January 02, 2026 | December 30, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 05, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 03, 2025 | August 27, 2025 | 2025 |
Continue your GNLX research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.